- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04759248
Study With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer (ATREZZO)
A Phase II With 2 Parallel Cohorts Clinical Trial Targeting Estrogen Receptor Negative or PAM50 Non-luminal Disease With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer - ATREZZO Study
Immune checkpoint inhibitors given in monotherapy in advanced breast cancer have shown modest benefit in first-line, but very limited efficacy in later lines. Thus, combination therapies are needed.
Response following anti-PD1/PD-L1 monotherapy is associated with large survival benefit in the advanced setting.
Previous studies of the intrinsic subtypes have shown that Basal-like and HER2-E are associated with higher expression of immune-related genes or higher infiltration of stromal tumor infiltrating lymphocytes compared to the luminal subtypes. Immune infiltration in BC is associated with chemo/antiHER2 responsiveness and potentially benefit from anti-PD-1/PD-L1 inhibitors.
In addition, one emerging biomarker of response to anti-PD-1 therapy is the tumor mutational burden (I.e. the total number of mutations per coding area of a tumor genome). The HER2-E and Basal-like profiles have been associated with high mutational burden.
A range of studies have been initiated including several phase II/III studies evaluating atezolizumab in combination with different chemotherapeutic compounds routinely used in breast cancer, but none with predefined biomarker beyond the expression of PD-L1 by IHC
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Alicante, Spain
- Recruiting
- Hospital General Universitario de Alicante
-
Principal Investigator:
- José Juan Ponce Lorenzo
-
Contact:
- Juan José Ponce Lorenzo
- Phone Number: +34 965 93 30 00
-
Barcelona, Spain, 08003
- Recruiting
- Hospital Del Mar
-
Contact:
- Sonia Servitja Tormo
- Phone Number: +34 932 48 30 00
-
Principal Investigator:
- Sonia Servitja Tormo, MD
-
Barcelona, Spain
- Recruiting
- Hospital Clinic de Barcelona
-
Contact:
- Olga Martinez
- Phone Number: +34 932 27 54 00
-
Principal Investigator:
- Olga Martínez, MD
-
Barcelona, Spain
- Recruiting
- Hospital Universitari Vall d' Hebron
-
Contact:
- Santiago Escrivá
- Phone Number: +34 934 89 30 00
-
Principal Investigator:
- Santiago Escrivá, MD
-
Cáceres, Spain
- Recruiting
- Hospital San Pedro de Alcántara
-
Principal Investigator:
- Santiago González, MD
-
Contact:
- Santiago Gonzalez
- Phone Number: +34 927 25 62 00
-
León, Spain, 24071
- Recruiting
- Hospital de Leon
-
Principal Investigator:
- Ana López, MD
-
Contact:
- Ana Lopez
- Phone Number: +34 987 23 74 00
-
Madrid, Spain
- Recruiting
- Hospital Universitario 12 de Octubre
-
Principal Investigator:
- Eva Ciruelos, MD
-
Contact:
- Eva Ciruelos
- Phone Number: +34 91 390 86 26
-
Palma De Mallorca, Spain
- Recruiting
- Hospital Son Espases
-
Principal Investigator:
- Antonia Perelló, MD
-
Contact:
- Antonia Perelló
- Phone Number: +34 871 20 50 00
-
Reus, Spain, 43201
- Recruiting
- Hospital Universitari Sant Joan de Reus
-
Contact:
- Cinta Albacar
- Phone Number: +34 977 31 03 00
-
Principal Investigator:
- Cinta Albacar, MD
-
Sevilla, Spain
- Recruiting
- Hospital Universitario Virgen del Rocio
-
Contact:
- Javier Salvador Bonfill
- Phone Number: +34 955 01 20 00
-
Principal Investigator:
- Javier Salvador Bonfill, MD
-
Valencia, Spain
- Recruiting
- Hospital Clinico Universitario de Valencia
-
Contact:
- Juan Miguel Cejalvo
- Phone Number: +34 961 97 35 00
-
Principal Investigator:
- Juan Miguel Cejalvo, MD
-
-
Andalucía
-
Granada, Andalucía, Spain
- Recruiting
- H. Clínico San Cecilio de Granada
-
Principal Investigator:
- Isabel Blancas, MD
-
Contact:
- Isabel Blancas
- Phone Number: +34 958 02 30 00
-
-
Barcelona
-
Hospitalet de Llobregat, Barcelona, Spain
- Recruiting
- Institut Catala d'Oncologia Hospitalet
-
Principal Investigator:
- Sonia Pernas, MD
-
Contact:
- Sonia Pernas
- Phone Number: +34 932 60 77 33
-
-
Islas Canarias
-
Tenerife, Islas Canarias, Spain, 38320
- Recruiting
- Hospital Universitario de Canarias
-
Contact:
- Josefina Cruz Jurado
- Phone Number: +34 922 67 80 00
-
Principal Investigator:
- Josefina Cruz Jurado, MD
-
-
La Coruña
-
A Coruña, La Coruña, Spain, 15006
- Recruiting
- Complejo Hospitalario Universitario A Coruña (CHUAC)
-
Contact:
- María E Perez López
- Phone Number: +34 981 178 000
-
Principal Investigator:
- Maria E Perez López, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female (Premenopausal or postmenopausal women)
- ECOG 0 to 2
- Histologically confirmed adenocarcinoma of the breast, metastatic or unresectable locally advanced.
- All patients must have received at least trastuzumab and other anti-HER2 ADCs (including but not limited to T-DM1).
- Measurable disease according to RECIST 1.1 criteria.
- Adequate organ function
- Baseline LVEF ≥50%
- Participants with asymptomatic brain metastases are eligible.
Exclusion Criteria:
- Treatment with any investigational anticancer drug within 14 days of the start of study treatment.
- Patient has received Vinorelbine or any other vinca alkaloids previously immediately prior to initiate study treatment.
- History of other malignant tumors in the past 3 years
- Known or suspected leptomeningeal disease (LMD)/ poorly controlled (> 1/week) generalized or complex partial seizures, or manifest neurologic progression due to brain metastases.
- Symptomatic hypercalcemia requiring treatment with bisphosphonates in the 14 days prior to inclusion
- Cardiopulmonary dysfunction
- Any other severe, uncontrolled
- Major surgery in the 28 days prior to enrolment
- Infection with HIV or active Hepatitis B and/or Hepatitis C.
- History of trastuzumab intolerance, including grade 3-4 infusion reaction or hypersensitivity.
- Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
- History of autoimmune disease,
- Prior allogeneic stem cell or solid organ transplantation
- History of idiopathic pulmonary fibrosis, drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan. (Note: History of radiation pneumonitis in the radiation field [fibrosis] is permitted.)
- Active tuberculosis
- Receipt of a live, attenuated vaccine within 4 weeks prior to enrollment
- Prior treatment with CD137 agonists, anti-PD-1, or anti-PD-L1 therapeutic antibody or immune checkpoint targeting agents
- Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin [IL]-2) within 4 weeks or five half-lives of the drug prior to enrolment
- Treatment with systemic immunosuppressive medications within 2 weeks prior to enrolment, or anticipated requirement for systemic immunosuppressive medications during the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Atezolizumab in combination with Trastuzumab and Vinorelbine
|
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response rate
Time Frame: until disease progression or up to 2 years after treatment ends
|
the proportion of patients with best overall response of complete response (CR) or partial response (PR), as per local investigator´s assessment and according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria
|
until disease progression or up to 2 years after treatment ends
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response rate in PD-L1+ patients
Time Frame: until disease progression or up to 2 years after treatment ends
|
the proportion of patients with best overall response of complete response (CR) or partial response (PR), as per local investigator´s assessment and according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria
|
until disease progression or up to 2 years after treatment ends
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Time Frame: until end of treatment / through study completion, an average of 1 year
|
AEs according to CTCAE v 5.0.
|
until end of treatment / through study completion, an average of 1 year
|
Overall Response rate in patients with brain metastases at baseline
Time Frame: Until disease progression or up to 2 years after treatment ends
|
Patients with a history of brain metastases, current brain metastases, or equivocal brain lesions at baseline
|
Until disease progression or up to 2 years after treatment ends
|
Clinical Benefit in patients with brain metastases at baseline
Time Frame: 24 weeks
|
Clinical Benefit Rate at 24 weeks in patients with a history of brain metastases, current brain metastases, or equivocal brain lesions at baseline
|
24 weeks
|
Progression free survival in patients with brain metastases at baseline
Time Frame: 24 weeks
|
Survival without observed progression in patients with a history of brain metastases, current brain metastases, or equivocal brain lesions at baseline
|
24 weeks
|
Overal survival in patients with brain metastases at baseline
Time Frame: Until analysis data cutoff, 2 years
|
Time from the date of allocation to the date of death due to any cause.
|
Until analysis data cutoff, 2 years
|
Clinical Benefit
Time Frame: 24 weeks
|
Clinical Benefit Rate at 24 weeks
|
24 weeks
|
Overal survival
Time Frame: Until analysis data cutoff, 2 years
|
Time from the date of allocation to the date of death due to any cause.
|
Until analysis data cutoff, 2 years
|
Progression free survival
Time Frame: 24 weeks
|
Survival witouth observed progression
|
24 weeks
|
Duration of response
Time Frame: 24 weeks
|
time from first documented response until progression
|
24 weeks
|
Time to response
Time Frame: 24 weeks
|
time until first documented response
|
24 weeks
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Trastuzumab
- Vinorelbine
- Atezolizumab
Other Study ID Numbers
- SOLTI-1907
- 2020-000245-13 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
Clinical Trials on Atezolizumab + Trastuzumab + Vinorelbine
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Beth Israel Deaconess Medical Center; Genentech... and other collaboratorsTerminatedBreast Cancer | Metastatic Breast CancerUnited States
-
National Cancer Institute, NaplesCompletedMetastatic Breast Cancer
-
Southwest Oncology GroupNational Cancer Institute (NCI)Completed
-
Fudan UniversityNot yet recruiting
-
Hoffmann-La RocheCompletedBreast CancerFrance, United States, Denmark, Germany, Spain, Italy, Brazil
-
Henan Cancer HospitalUnknown
-
Danish Breast Cancer Cooperative GroupSanofi; Hoffmann-La RocheUnknown
-
National Cancer Institute, NaplesActive, not recruitingMetastatic Breast CancerItaly
-
Dartmouth-Hitchcock Medical CenterNational Cancer Institute (NCI)Completed
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedBreast CancerUnited States